ONTX
NASDAQOnconova Therapeutics Inc.
Latest news
25 items- SECSEC Form 10-K/A filed by Onconova Therapeutics Inc. (Amendment)10-K/A - Traws Pharma, Inc. (0001130598) (Filer)
- SECSEC Form D filed by Onconova Therapeutics Inc.D - Traws Pharma, Inc. (0001130598) (Filer)
- SECSEC Form DEFA14A filed by Onconova Therapeutics Inc.DEFA14A - Traws Pharma, Inc. (0001130598) (Filer)
- SECOnconova Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Traws Pharma, Inc. (0001130598) (Filer)
- INSIDERNew insider Orbimed Advisors Llc claimed ownership of 1,045,261 shares (SEC Form 3) (Amendment)3/A - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERNew insider Tpav, Llc claimed ownership of 1,222,738 shares (SEC Form 3) (Amendment)3/A - Traws Pharma, Inc. (0001130598) (Issuer)
- 13D/GSEC Form SC 13D filed by Onconova Therapeutics Inc.SC 13D - Traws Pharma, Inc. (0001130598) (Subject)
- INSIDERRedfield Robert was granted 97,500 shares (SEC Form 4)4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERPauza Charles David was granted 97,500 shares (SEC Form 4)4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERCautreels Werner was granted 200,000 shares (SEC Form 4)4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSavchuk Nikolay was granted 2,664,869 shares (SEC Form 4)4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERDukes Iain D. was granted 1,779,337 shares (SEC Form 4)4 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERNew insider Viriom, Inc. claimed ownership of 1,645,100 shares (SEC Form 3)3 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERNew insider Orbimed Advisors Llc claimed ownership of 885,532 shares (SEC Form 3)3 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 3 filed by new insider Redfield Robert3 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 3 filed by new insider Pauza Charles David3 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cautreels Werner3 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERNew insider Tpav, Llc claimed ownership of 885,532 shares (SEC Form 3)3 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 3 filed by new insider Savchuk Nikolay3 - Traws Pharma, Inc. (0001130598) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dukes Iain D.3 - Traws Pharma, Inc. (0001130598) (Issuer)
- NEWSOnconova Therapeutics shares are trading lower after the company announced that it entered into a definitive merger agreement to acquire 100% of Trawsfynydd's outstanding equity interests.
- PRTraws Pharma Announces New Employee Inducement GrantsNEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW, "Traws", the "Company"))) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. (the "Merger"). On April 1, 2024, Traws granted restricted stock equity awards to Werner Cautreels, Iain Dukes, Nikolay Savchuk, C. David Pauza and Robert Redfield, as an inducement for each of them to accept employment, which equity awards relate to, 200,000, 67,500, 67,500, 97,500 and 97,500 shares of Traws common stock. One-quarter (1/4) of the shares subject to each restricted stock equity awar
- NEWSOnconova Therapeutics, Inc. And Trawsfynydd Therapeutics, Inc. Announce All-Stock Business Combination, Under Agreement, Onconova Acquired 100% Of Trawsfynydd's Outstanding Equity Shares With A Combined Fully Diluted Equity Value Of $132M; In Connection, Traws Will Raise $14M In Committed Private Placement Financing
- PROnconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology CompanyClosing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey PinesFunding expected to advance development of three potential best-in-class/class leading assets: viroksavir, a cap-dependent endonuclease inhibitor for influenza; travaltrelvir, a protease inhibitor for COVID19; and narazaciclib, a next generation CDK4/6 inhibitor for low grade endometriod endometrial cancer (LGEEC)Multiple near-term catalysts, for viroksavir and travaltrevir in 2024, with first top-line read-outs expected in H2 2024Traws Pharma to be led by incoming CEO, Werner Cautreels, Ph.D. Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) alo
- SECSEC Form 10-K filed by Onconova Therapeutics Inc.10-K - Onconova Therapeutics, Inc. (0001130598) (Filer)
ONTX FAQ
7 questionsWhat does Onconova Therapeutics Inc. do?
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and...Where does ONTX stock trade?
Onconova Therapeutics Inc. (ONTX) is listed on NASDAQ.What sector and industry is ONTX in?
Onconova Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Onconova Therapeutics Inc. go public?
Onconova Therapeutics Inc. (ONTX) completed its IPO in 2013.What are analysts saying about ONTX?
Onconova Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from Ladenburg Thalmann: Buy with a $700.00 price target on 2022-03-01. Recent price targets cluster around $700.00.What companies are similar to ONTX?
Notable peers in the same industry include CBAY (CymaBay Therapeutics Inc.), MCRB (Seres Therapeutics Inc.), ALRN (Aileron Therapeutics Inc.). Compare ONTX side-by-side with any of them on Quantisnow.How can I track ONTX on Quantisnow?
Quantisnow aggregates Onconova Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ONTX to receive live email and push alerts on every new disclosure.